|
|
|
|
LEADER |
03959nam a2200853Ia 4500 |
001 |
10-1172-jci-insight-155483 |
008 |
220420s2022 CNT 000 0 und d |
020 |
|
|
|a 23793708 (ISSN)
|
245 |
1 |
0 |
|a Duration of viral shedding and culture positivity with postvaccination SARSCoV-2 delta variant infections
|
260 |
|
0 |
|b American Society for Clinical Investigation
|c 2022
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1172/jci.insight.155483
|
520 |
3 |
|
|a Isolation guidelines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are largely derived from data collected prior to the emergence of the delta variant. We followed a cohort of ambulatory patients with postvaccination breakthrough SARS-CoV-2 infections with longitudinal collection of nasal swabs for SARS-CoV-2 viral load quantification, whole-genome sequencing, and viral culture. All delta variant infections in our cohort were symptomatic, compared with 64% of non-delta variant infections. Symptomatic delta variant breakthrough infections were characterized by higher initial viral load, longer duration of virologic shedding by PCR, greater likelihood of replication-competent virus at early stages of infection, and longer duration of culturable virus compared with non-delta variants. The duration of time since vaccination was also correlated with both duration of PCR positivity and duration of detection of replication-competent virus. Nonetheless, no individuals with symptomatic delta variant infections had replication-competent virus by day 10 after symptom onset or 24 hours after resolution of symptoms. These data support US CDC isolation guidelines as of November 2021, which recommend isolation for 10 days or until symptom resolution and reinforce the importance of prompt testing and isolation among symptomatic individuals with delta breakthrough infections. Additional data are needed to evaluate these relationships among asymptomatic and more severe delta variant breakthrough infections. Copyright: © 2022, Siedner et al.
|
650 |
0 |
4 |
|a administration and dosage
|
650 |
0 |
4 |
|a adult
|
650 |
0 |
4 |
|a Adult
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a clinical article
|
650 |
0 |
4 |
|a cohort analysis
|
650 |
0 |
4 |
|a coronavirus disease 2019
|
650 |
0 |
4 |
|a COVID-19
|
650 |
0 |
4 |
|a COVID-19 Vaccines
|
650 |
0 |
4 |
|a female
|
650 |
0 |
4 |
|a Female
|
650 |
0 |
4 |
|a genetics
|
650 |
0 |
4 |
|a human
|
650 |
0 |
4 |
|a Humans
|
650 |
0 |
4 |
|a isolation
|
650 |
0 |
4 |
|a male
|
650 |
0 |
4 |
|a Male
|
650 |
0 |
4 |
|a metabolism
|
650 |
0 |
4 |
|a middle aged
|
650 |
0 |
4 |
|a Middle Aged
|
650 |
0 |
4 |
|a nonhuman
|
650 |
0 |
4 |
|a nose smear
|
650 |
0 |
4 |
|a physiology
|
650 |
0 |
4 |
|a polymerase chain reaction
|
650 |
0 |
4 |
|a practice guideline
|
650 |
0 |
4 |
|a prevention and control
|
650 |
0 |
4 |
|a SARS-CoV-2
|
650 |
0 |
4 |
|a SARS-CoV-2 Delta
|
650 |
0 |
4 |
|a symptom
|
650 |
0 |
4 |
|a time factor
|
650 |
0 |
4 |
|a Time Factors
|
650 |
0 |
4 |
|a vaccination
|
650 |
0 |
4 |
|a virus culture
|
650 |
0 |
4 |
|a virus load
|
650 |
0 |
4 |
|a virus replication
|
650 |
0 |
4 |
|a virus replication
|
650 |
0 |
4 |
|a Virus Replication
|
650 |
0 |
4 |
|a virus shedding
|
650 |
0 |
4 |
|a virus shedding
|
650 |
0 |
4 |
|a Virus Shedding
|
650 |
0 |
4 |
|a whole genome sequencing
|
700 |
1 |
0 |
|a Barczak, A.K.
|e author
|
700 |
1 |
0 |
|a Boucau, J.
|e author
|
700 |
1 |
0 |
|a Chamberlin, G.C.
|e author
|
700 |
1 |
0 |
|a Choudhary, M.C.
|e author
|
700 |
1 |
0 |
|a Flynn, J.P.
|e author
|
700 |
1 |
0 |
|a Gilbert, R.F.
|e author
|
700 |
1 |
0 |
|a Goldstein, R.H.
|e author
|
700 |
1 |
0 |
|a Haneuse, S.
|e author
|
700 |
1 |
0 |
|a Iyer, S.
|e author
|
700 |
1 |
0 |
|a Lemieux, J.E.
|e author
|
700 |
1 |
0 |
|a Li, J.Z.
|e author
|
700 |
1 |
0 |
|a Luu, J.
|e author
|
700 |
1 |
0 |
|a North, C.M.
|e author
|
700 |
1 |
0 |
|a Regan, J.
|e author
|
700 |
1 |
0 |
|a Reynolds, Z.
|e author
|
700 |
1 |
0 |
|a Sacks, C.A.
|e author
|
700 |
1 |
0 |
|a Siedner, M.J.
|e author
|
700 |
1 |
0 |
|a Uddin, R.
|e author
|
700 |
1 |
0 |
|a Vyas, J.M.
|e author
|
700 |
1 |
0 |
|a Vyas, T.
|e author
|
773 |
|
|
|t JCI Insight
|